FGFR1 and non-small cell lung carcinoma: Activation of the FGF2/FGFR1 autocrine pathway in EGFR-dependent NSCLC leads to resistance to gefitinib and osimertinib, indicating a potential connection between the FGFR and EGFR pathways (206, 207).